OncoMatch

OncoMatch/Clinical Trials/NCT07214961

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Is NCT07214961 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AB001 for prostate cancer (crpc).

Phase 1RecruitingARTBIO Inc.NCT07214961Data as of May 2026

Treatment: AB001 — This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced. The study includes dose escalation to identify a recommended dose and dose expansion to further assess safety and anti-tumour activity. Primary objectives are to characterize the safety profile and determine the optimal dose and schedule for future studies

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Biomarker criteria

Required: FOLH1 psma-avid lesion

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: androgen receptor pathway inhibitor

Previous treatment with at least one novel ARPI

Must have received: androgen deprivation therapy

Prior orchiectomy and/or prior or ongoing androgen-deprivation therapy

Must have received: taxane

Prior treatment with at least one taxane regimen or patient refusing or considered appropriate by treating physician to delay taxane therapy

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • BAMF Health · Grand Rapids, Michigan
  • XCancer · Omaha, Nebraska
  • United Theranostics · Princeton, New Jersey

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify